Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.

While this was not a randomized controlled trial, Novo said the findings provide evidence that the heart-protective benefits of Wegovy and its main ingredient semaglutide may not be the same for all GLP-1 drugs, such as tirzepatide, the active ingredient in Zepbound and Mounjaro.

Compared with tirzepatide, a 2.4 milligram dose of Wegovy showed a significant 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause while on treatment with no gaps of more than

See Full Page